 This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis ALS to explore safety, tolerability, and pharmacokinetic PK properties of GDC-0134. It will include two components: a Single-Ascending-Dose SAD stage and a Multiple-Ascending-Dose MAD stage. 